Repligen (RGEN) is higher today as investors react to new bullish analyst coverage that initiated the stock at Buy with a $160 price target, framing Repligen as a differentiated pure-play in bioprocessing with exposure to higher-intensity segments of biologics manufacturing. The initiation call pointed to strength in areas such as ATF-based cell retention and in-line process analytical technology, supporting expectations for durable growth and margins.

The upgrade-style catalyst is landing on top of a still-fresh fundamental backdrop: Repligen recently reported quarterly results ahead of expectations (EPS $0.49 vs $0.44; revenue $197.9 million vs $192.2 million) and set FY2026 EPS guidance of $1.93–$2.01. With the stock trading well below prior highs, incremental positive research notes are having outsized impact as investors re-price the earnings path and the timing of bioprocessing demand normalization.

With shares around $128, the $160 target implies meaningful upside if Repligen executes on guidance and order trends remain steady across filtration, chromatography, and analytics. Investors will be focused on updates to orders/backlog, mix shifts between clinical and commercial demand, and any signals that consumables-driven recurring revenue can sustain growth as customers progress programs from clinical to commercial scale.